Effects of methimazole on the elimination of irinotecan
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
PURPOSE: To study the possible pharmacokinetic and pharmacodynamic interactions between irinotecan and methimazole. METHODS: A patient treated for colorectal cancer with single agent irinotecan received methimazole co-medication for Graves' disease. Irinotecan pharmacokinetics and side effects were followed during a total of four courses (two courses with and two courses without methimazole). RESULTS: Plasma concentrations of the active irinotecan metabolite SN-38 and its inactive metabolite SN-38-Glucuronide were both higher (a mean increase of 14 and 67%, respectively) with methimazole co-medication, compared to irinotecan monotherapy. As a result, the mean SN-38 glucuronidation rate increased with 47% during concurrent treatment. Other possible confounding factors did not change over time. Specific adverse events due to methimazole co-treatment were not seen. CONCLUSIONS: Additional in vitro experiments suggest that these results can be explained by induction of UGT1A1 by methimazole, leading to higher SN-38G concentrations. The prescribed combination of these drugs may lead to highly toxic intestinal SN-38 levels. We therefore advise physicians to be very careful in combining methimazole with regular irinotecan doses, especially in patients who are prone to irinotecan toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Methimazole (CYP3A inhibitor) [108], neomycin (β-glucuronidase inhibitor) [109] and amoxapine (β-glucuronidase inhibitor) [110] have been shown to reduce SN-38 degradation effectively.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [108]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Self-citationBurger, H., van Tol, H., Boersma, A. W. M., Brok, M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2004) · Blood · doi:10.1182/blood-2004-04-1398 · Cited by 417 · cited 1×
“The mitoxantrone accumulation (Xuorescence intensity) was determined by Xow cytometry as described previously [ 20 ].”
MethodSelf-citationTakasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1996) · PubMed · Cited by 336
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
Vanhoefer, U., Harstrick, A., Achterrath, W., Cao, S., Seeber, S., & Rustum, Y. M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1501 · Cited by 326 · cited 1×
“Irinotecan is extensively used in the treatment of advanced colorectal cancer [1].”
BackgroundComprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Innocenti, F., Kroetz, D. L., Schuetz, E., Dolan, M. E., Ramírez, J., Relling, M., Chen, P., Das, S., Rosner, G. L., & Ratain, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6300 · Cited by 262 · cited 2×
“The patient appeared to be wild-type (TA6/TA6) for UGT1A1*28, meaning that UGT1A1 function was not lowered based on this familiar genetic polymorphism [3].”
BackgroundModulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients.
Kehrer, D. F. S., Sparreboom, A., Verweij, J., de Bruijn, P., Nierop, C. A., van de Schraaf, J., Ruijgrok, E. J., & de Jonge, M. J. (2001) · PubMed · Cited by 176
Self-citationSlatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., & Wienkers, L. C. (1997) · PubMed · Cited by 152
Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia.
van der Bol, J. M., Mathijssen, R. H. J., Loos, W. J., Friberg, L. E., van Schaik, R. H. N., de Jonge, M. J. A., Planting, A. S. T., Verweij, J., Sparreboom, A., & de Jong, F. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6115 · Cited by 128 · cited 4×
“Irinotecan drug-concentrations assessed in the courses without methimazole are within the low-normal range of literature data [ 6 , 12, 13], possibly due to patients’ smoking behavior.”
BackgroundMethodSelf-citationModulation of Irinotecan Metabolism by Ketoconazole
Kehrer, D. F. S., Mathijssen, R. H. J., Verweij, J., de Bruijn, P., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.177 · Cited by 124 · cited 1×
“Irinotecan drug-concentrations assessed in the courses without methimazole are within the low-normal range of literature data [6, 12, 13], possibly due to patients’ smoking behavior.”
BackgroundSelf-citationTakasuna, K., Hagiwara, T., Hirohashi, M., Kato, M., Nomura, M., Nagai, E., Yokoi, T., & Kamataki, T. (1998) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050818 · Cited by 120
Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea
Xie, R., Mathijssen, R. H. J., Sparreboom, A., Verweij, J., & Karlsson, M. O. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.126741 · Cited by 116 · cited 1×
“This was also shown in a population-pharmacokinetic model of irinotecan, in which the AUC of SN-38G was correlated with diarrhea scores (P 16 ].”
ResultSelf-citationOrphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes.
Guo, Z., Raeissi, S., White, R. B., & Stevens, J. C. (1997) · PubMed · Cited by 82
Sparreboom, A., de Bruijn, P., de Jonge, M. J. A., Loos, W. J., Stoter, G., Verweij, J., & Nooter, K. (1998) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(98)00147-9 · Cited by 78 · cited 1×
“Plasma concentrations of irinotecan, NPC, APC, SN-38, and SN-38G were determined using validated chromatography methods [9, 10].”
MethodSelf-citationEffects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes
Yong, W. P., Ramírez, J., Innocenti, F., & Ratain, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0703 · Cited by 73
Van Steenbergen, W., Fevery, J., De Vos, R., Leyten, R., Heirwegh, K. P. M., & De Groote, J. (1989) · Hepatology · doi:10.1002/hep.1840090225 · Cited by 73
Tobin, P. J., Beale, P. J., Noney, L., Liddell, S., Rivory, L. P., & Clarke, S. J. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0053-0 · Cited by 49 · cited 1×
“Irinotecan drug-concentrations assessed in the courses without methimazole are within the low-normal range of literature data [6, 12, 13], possibly due to patients’ smoking behavior.”
BackgroundThyroid hormones and the hepatic handling of bilirubin
Steenbergen, W. V., Fevery, J., & de Groote, J. (1988) · Journal of Hepatology · doi:10.1016/s0168-8278(88)80487-2 · Cited by 29
Lifestyle habits as a contributor to anti-cancer treatment failure
de Jong, F. A., Sparreboom, A., Verweij, J., & Mathijssen, R. H. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.012 · Cited by 27
Self-citationClinical Pharmacokinetics of Irinotecan-Based Chemotherapy in Colorectal Cancer Patients
Paolo, A. D., Bocci, G., Danesi, R., & Tacca, M. D. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406778249307 · Cited by 26 · cited 1×
“SN-38G, which facilitates excretion from the circulation [2].”
BackgroundVisser, T. J., Kaptein, E., Gijzel, A. L., de Herder, W. W., Cannon, M. L., Bonthuis, F., & GREEF, W. J. D. (1996) · Endocrine · doi:10.1007/bf02738878 · Cited by 18 · cited 2×
“As SN-38 levels are only moderately increased, while SN-38G concentrations are much higher in the presence of methimazole, our clinical data support the preclinical literature describing combined eVects of CYP3Ainhibition and UGT1A-induction by methimazole [7, 8 ]. However, inhibition of CYP3A was not conWrmed by lowe…”
BackgroundResultSelf-citationde Bruijn, P., Willems, E. W., Loos, W. J., Verweij, J., & Sparreboom, A. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.01.007 · Cited by 15
Self-citation
Cited by
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
“In contrast, by UGT1A induction by methimazole, an increase in SN-38 and SN-38G concentrations, as well as an almost 50% increased ratio of SN38G/SN-38, was found by within-patient comparison (Table 1) [150].”
ResultSelf-citationDrug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Quantitative Investigation of Irinotecan Metabolism, Transport, and Gut Microbiome Activation
Parvez, M. M., Basit, A., Jariwala, P. B., Gáborik, Z., Kis, E., Heyward, S. A., Redinbo, M. R., & Prasad, B. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000476 · Cited by 86
Miners, J. O., Polasek, T. M., Hulin, J.-A., Rowland, A., & Meech, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108459 · Cited by 70
Chu, C., Abbara, C., Tandia, M., Polrot, M., Gonin, P., Farinotti, R., & Bonhomme‐Faivre, L. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12071 · Cited by 14
Metadata
- Authors
- van der Bol, J. M., Visser, T. J., Loos, W. J., de Jong, F. A., Wiemer, E. A. C., van Aken, M. O., Planting, A. S., Schellens, J. H., Verweij, J., & Mathijssen, R. H. J.
- Affiliations
- Erasmus MC (NL)
- Utrecht University (NL)
- Corresponding author
- Mathijssen, Ron H. J.
- ORCID
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2010-08-01
- Volume
- 67
- Issue
- 1
- Pages
- 231-236
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC3016232
- OpenAlex
- W2114917381
- Cited by
- 9
- References
- 21
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2018: 1 · 2015: 1 · 2014: 2 · 2012: 1
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- irinotecan, methimazole, drug-drug interactions, SN-38, SN-38 glucuronide, SN-38 glucuronidation, pharmacokinetic interactions, pharmacodynamic interactions, colorectal cancer, Graves' disease, irinotecan toxicity, intestinal toxicity
- MeSH terms
- Irinotecan, UGT1A1 Enzyme, Antineoplastic Agents, Phytogenic, Camptothecin, Drug Interactions, Graves Disease, Humans, Male, Methimazole, Middle Aged, Antithyroid Agents, Glucuronosyltransferase, Colorectal Neoplasms, Glucuronides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.